Rapamycin for Women: Ovarian Aging and Menopause Timing

Columbia's trial — VIBRANT, for Validating Benefits of Rapamycin for Reproductive Aging Treatment — enrolled around fifty women in their late thirties to mid-forties, randomized them to a weekly rapamycin tablet or placebo for three months, and measured ovarian reserve with ultrasound follicle counts and anti-Müllerian hormone. The preliminary results, presented in 2024, reported that the rapamycin group showed a slower decline in ovarian reserve — described by the investigators as roughly a twenty percent reduction in the rate of ovarian aging — with no significant side effects and no change in menstrual cycles.

That is the whole of the human evidence. Fifty women. Three months. A surrogate marker. Preliminary results. A larger phase 2 trial of around a thousand women was planned to follow; if it has reported, its results supersede everything here.

Three months is long enough to see a change in a marker and nowhere near long enough to see a change in the thing the marker stands for. Whether a slower fall in AMH over twelve weeks translates into a later menopause, a longer fertile window, or better health after menopause is unknown and will take years to learn. The "five years" figure in the headlines was an extrapolation from the pilot's rate, not an observation.

Safety over years is equally unknown. Rapamycin's known effects on the ovary in transplant patients — where it is used continuously at much higher exposure — include menstrual irregularities and ovarian cysts, which cut against the simple story. The intermittent, lower-exposure use in VIBRANT did not show these in three months; longer use may or may not.

And there is a hard rule that applies to every woman who could conceive: rapamycin must not be taken in pregnancy. It caused harm to the fetus in animal studies, it crosses into breast milk, and reliable contraception during use and for a period after stopping is a requirement, not a suggestion. For a woman taking it precisely because she hopes to preserve her fertility, that is an irony the trial protocols handle carefully and a home prescription must handle just as carefully.

Probably less than she hopes, and for a clear reason: the VIBRANT women were in their late thirties to mid-forties, with ovarian reserve to preserve. A woman at forty-eight or fifty-two, in perimenopause or past it, has a reserve that is already low or exhausted, and there is no evidence — and little theoretical reason to expect — that rapamycin restores what is gone. It is a preservation hypothesis, not a reversal one.

That does not make rapamycin irrelevant to a woman over forty-five. The general longevity case on the main page applies to her as much as to a man, and the animal lifespan data, if anything, favor females. But the ovarian story is not her story, and the symptoms she is dealing with — hot flushes, sleep, mood, bone, the genitourinary changes — have treatments with decades of evidence on the women's HRT page. A woman who takes rapamycin instead of addressing perimenopause is trading a proven treatment for a speculative one.

For the woman in her late thirties or early forties who is reading this with her fertility in mind: the honest advice is that this is a research question, that a fertility specialist is the right person to discuss it with, and that if she is seriously considering it, enrolling in a trial gives her the drug under monitoring and gives the question an answer.

We prescribe rapamycin to women on the same basis as to men — the longevity rationale, the candidacy and monitoring on the main page, the interaction check, the labs. We ask every woman who could conceive about contraception and require it. We do not prescribe rapamycin to preserve fertility or delay menopause, because the evidence is a three-month pilot, and we say so. And if the phase 2 trial reports and changes that picture, this page will change with it.